Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Medulloblastoma Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Medulloblastoma Overview | 10 | 1 |
| Pipeline Products for Medulloblastoma Comparative Analysis | 11 | 1 |
| Medulloblastoma Therapeutics under Development by Companies | 12 | 1 |
| Medulloblastoma Therapeutics under Investigation by Universities/Institutes | 13 | 1 |
| Medulloblastoma Pipeline Products Glance | 14 | 3 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Unknown Stage Products | 16 | 1 |
| Medulloblastoma Products under Development by Companies | 17 | 1 |
| Medulloblastoma Products under Investigation by Universities/Institutes | 18 | 1 |
| Medulloblastoma Companies Involved in Therapeutics Development | 19 | 12 |
| Bayer AG | 19 | 1 |
| DelMar Pharmaceuticals, Inc. | 20 | 1 |
| Ignyta, Inc. | 21 | 1 |
| Lipocure Ltd. | 22 | 1 |
| MacroGenics, Inc. | 23 | 1 |
| Medicenna Therapeutics, Inc. | 24 | 1 |
| MEI Pharma, Inc. | 25 | 1 |
| Novartis AG | 26 | 1 |
| Novogen Limited | 27 | 1 |
| Progenics Pharmaceuticals, Inc. | 28 | 1 |
| Stemline Therapeutics, Inc. | 29 | 1 |
| Takeda Pharmaceutical Company Limited | 30 | 1 |
| Medulloblastoma Therapeutics Assessment | 31 | 10 |
| Assessment by Monotherapy Products | 31 | 1 |
| Assessment by Combination Products | 32 | 1 |
| Assessment by Target | 33 | 2 |
| Assessment by Mechanism of Action | 35 | 2 |
| Assessment by Route of Administration | 37 | 2 |
| Assessment by Molecule Type | 39 | 2 |
| Drug Profiles | 41 | 30 |
| (topotecan hydrochloride + vincristine sulfate) - Drug Profile | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 1 |
| Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| R&D Progress | 42 | 1 |
| dianhydrogalactitol - Drug Profile | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 3 |
| Edotreotide Labeled Yttrium 90 - Drug Profile | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 2 |
| irinotecan hydrochloride + TBio-02 - Drug Profile | 48 | 1 |
| Product Description | 48 | 1 |
| Mechanism of Action | 48 | 1 |
| R&D Progress | 48 | 2 |
| LEQ-506 - Drug Profile | 50 | 1 |
| Product Description | 50 | 1 |
| Mechanism of Action | 50 | 1 |
| R&D Progress | 50 | 1 |
| MDNA-55 - Drug Profile | 51 | 1 |
| Product Description | 51 | 1 |
| Mechanism of Action | 51 | 1 |
| R&D Progress | 51 | 1 |
| Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma and Medulloblastoma - Drug Profile | 52 | 1 |
| Product Description | 52 | 1 |
| Mechanism of Action | 52 | 1 |
| R&D Progress | 52 | 1 |
| Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile | 53 | 1 |
| Product Description | 53 | 1 |
| Mechanism of Action | 53 | 1 |
| R&D Progress | 53 | 1 |
| nifurtimox - Drug Profile | 54 | 1 |
| Product Description | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| R&D Progress | 54 | 1 |
| nifurtimox SR - Drug Profile | 55 | 1 |
| Product Description | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| R&D Progress | 55 | 1 |
| p28 - Drug Profile | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 2 |
| pracinostat - Drug Profile | 58 | 1 |
| Product Description | 58 | 1 |
| Mechanism of Action | 58 | 1 |
| R&D Progress | 58 | 2 |
| siomycin A - Drug Profile | 60 | 1 |
| Product Description | 60 | 1 |
| Mechanism of Action | 60 | 1 |
| R&D Progress | 60 | 1 |
| SL-301 - Drug Profile | 61 | 1 |
| Product Description | 61 | 1 |
| Mechanism of Action | 61 | 1 |
| R&D Progress | 61 | 1 |
| Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile | 62 | 1 |
| Product Description | 62 | 1 |
| Mechanism of Action | 62 | 1 |
| R&D Progress | 62 | 1 |
| taladegib - Drug Profile | 63 | 1 |
| Product Description | 63 | 1 |
| Mechanism of Action | 63 | 1 |
| R&D Progress | 63 | 2 |
| THR-317 - Drug Profile | 65 | 1 |
| Product Description | 65 | 1 |
| Mechanism of Action | 65 | 1 |
| R&D Progress | 65 | 3 |
| Trilexium - Drug Profile | 68 | 1 |
| Product Description | 68 | 1 |
| Mechanism of Action | 68 | 1 |
| R&D Progress | 68 | 2 |
| VMY-1103 - Drug Profile | 70 | 1 |
| Product Description | 70 | 1 |
| Mechanism of Action | 70 | 1 |
| R&D Progress | 70 | 1 |
| Medulloblastoma Recent Pipeline Updates | 71 | 18 |
| Medulloblastoma - Dormant Projects | 89 | 1 |
| Medulloblastoma Product Development Milestones | 90 | 5 |
| Featured News &Press Releases | 90 | 1 |
| Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083 | 90 | 1 |
| Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant | 91 | 1 |
| Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors | 91 | 2 |
| Sep 19, 2011: Researchers Discover Regulatory Protein As Potential Drug Target For Brain Tumors | 93 | 2 |
| Appendix | 95 | 2 |
| Methodology | 95 | 1 |
| Coverage | 95 | 1 |
| Secondary Research | 95 | 1 |
| Primary Research | 95 | 1 |
| Expert Panel Validation | 95 | 1 |
| Contact Us | 95 | 1 |
| Disclaimer | 96 | 1 |